Time, Fuel, & Money
Time, Fuel, and Money is a conversation for founders, investors, operators, and high-performers who want to understand the deeper forces that shape how we live, build, lead, and make decisions. Hosted by Deborah Moorad, Karim ReFaey, and Vassili Kotlov, the show blends neuroscience, psychology, business, energy, and human behavior—turning complex ideas into practical, emotionally intelligent frameworks.
Each week, we explore what really drives progress: alignment, awareness, relationships, incentives, momentum, and the hidden energy behind ambition. Through stories from biotech, venture capital, government, aviation, engineering, and everyday life, we break down how time, fuel, and money work together—and how they quietly shape careers, companies, and character.
This is not a hustle show. It’s a clarity show.
A place to think deeper, grow wiser, and operate with more intention—without losing your humanity.
New episodes weekly. Join us and rethink the rules.
Time, Fuel, & Money
BLPN: Delivery Wins. Help First. Build Anyway.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Fundraising, platform leverage, and the relationships that make biotech move.
BLPN Series | Episode 4 of 4
As JPM week approaches, we close the BLPN Series with a founder conversation that sits right at the intersection of science, capital, and the human reality of building.
Deborah and Karim are joined by Regina Leung, CEO of Sylamore Bio, a gene therapy company advancing rare disease programs while building a CNS delivery platform designed to cross the blood-brain barrier. Regina shares how Silimot is using a dual-track strategy: moving a lead rare-disease indication toward the clinic while leveraging platform partnerships to validate the tech, generate revenue, and de-risk development.
The conversation gets practical about what “raising in a hard market” actually looks like: why platform companies are often misunderstood, why chasing buzzwords backfires, and why founders are better served by 10 high-quality conversations than “a thousand frogs.” We also unpack the operational side—how to scale a team carefully, avoid hiring mistakes, and stay disciplined when partnership milestones demand more capacity.
We end where biotech always ends: with patients. Regina shares a sobering reminder of what’s at stake in ultra-rare disease—and why optimism isn’t naïve when it’s paired with execution, humility, and community.
This episode is about staying authentic, building the right relationships, and remembering that delivery—of drugs, of leadership, of help—wins.